How cytomegalorvirus reactivation could cause pulmonary pathology in septic hosts.
Heininger
Alexandra
A
Hamprecht
Klaus
K
D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use; D003587:Cytomegalovirus / Q000276:immunology / Q000502:physiology*; D015774:Ganciclovir / Q000627:therapeutic use; D006801:Humans; D007121:Immunocompetence; D008168:Lung / Q000473:pathology / Q000821:virology*; D051379:Mice; D011658:Pulmonary Fibrosis / Q000517:prevention & control / Q000821:virology; D018805:Sepsis / Q000150:complications*; D014775:Virus Activation / Q000187:drug effects / Q000276:immunology
D000998:Antiviral Agents; D015774:Ganciclovir